{
    "clinical_study": {
        "@rank": "127720", 
        "acronym": "EFFECT-AF", 
        "arm_group": [
            {
                "arm_group_label": "Patients treated with dronedarone", 
                "description": "Patients treated with dronedarone at inclusion"
            }, 
            {
                "arm_group_label": "Patients treated with other antiarrhythmic drugs of interest", 
                "description": "The antiarrhythmic drugs of interest to which dronedarone will be compared are:\nClass 1a/1c antiarrhythmics\nSotalol\nAmiodarone"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an international observational multicentre study to be conducted in Germany, Spain,\n      Italy and USA. The main objective of the study is to evaluate the relative effectiveness of\n      dronedarone in real world clinical practice versus other anti-arrhythmic agents of interest.\n      The design of the study is a historic-prospective cohort with dynamic exposure and\n      stratified competitive recruitment with balanced comparison groups of dronedarone versus\n      alternative antiarrhythmic drugs of interest."
        }, 
        "brief_title": "Effectiveness Study of Atrial Fibrillation", 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient 18 years old or above\n\n          -  Patient with paroxysmal or persistent atrial fibrillation\n\n          -  Patient using an AAi (antiarrhythmic drug of interest) or dronedarone (index drug)\n\n          -  Patient's treatment changed from one AAi to another AAi or dronedarone OR from no\n             antiarrhythmic therapy to the start of AAi or dronedarone therapy during previous 6\n             months before the date of recruitment\n\n          -  Patient with at least 6 months of medical and treatment information prior to the\n             start of the index drug\n\n          -  Patient able to answer the telephone interview in a language of the participating\n             country: English, German, Italian or Spanish (with or without proxy).\n\n        Exclusion Criteria:\n\n          -  Patient with heart failure (NYHA class IV)\n\n          -  Patient with permanent Atrial Fibrillation\n\n          -  Patient with psychiatric conditions preventing the participation to the study\n             according to the physician"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "This is an international observational multicentre study to be conducted in the following\n        four countries: Germany, Spain, Italy and USA. Patients will be will be recruited from\n        cardiology clinics, both hospital and non-hospital based, depending on particulars of\n        treatment pathway of ppAF patients in each country."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01856075", 
            "org_study_id": "Sanofi-EFFECT-AF"
        }, 
        "intervention_browse": {
            "mesh_term": "Anti-Arrhythmia Agents"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Atrial Fibrillation", 
            "Dronedarone", 
            "Cohort", 
            "Effectiveness"
        ], 
        "lastchanged_date": "May 16, 2013", 
        "location": {
            "contact": {
                "email": "klingenheben@bonn-kardiologie.de", 
                "last_name": "Thomas Klingenheben, MD", 
                "phone": "0049 228 62 33 24"
            }, 
            "facility": {
                "address": {
                    "city": "Bonn", 
                    "country": "Germany", 
                    "zip": "53127"
                }, 
                "name": "Praxis fuer Kardiologie, Im Muehlenbach 2B"
            }, 
            "investigator": {
                "last_name": "Thomas Klingenheben, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "2", 
        "official_title": "Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillation", 
        "overall_official": {
            "affiliation": "LA-SER Europe", 
            "last_name": "Artak Khachatryan, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: The European Medicines Agency's (EMA)", 
                "United Kingdom: Committee for Medicinal Products for Human Use (CHMP)"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of the recurrence of atrial fibrillation (change from baseline) at 3 month, 6 month, and 12-18 month of follow-up", 
            "measure": "Change from baseline Recurrence of Atrial Fibrillation", 
            "safety_issue": "No", 
            "time_frame": "3 month; 6 month; 12-18 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01856075"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline Cardiovascular hospitalisation", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline AV node ablation and catheter ablation for Atrial Fibrillation", 
                "safety_issue": "No", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Progression to permanent Atrial Fibrillation", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Clinical progression to heart failure and left ventricular systolic dysfunction", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Congestive heart failure", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Interstitial pulmonary disease", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Liver injury/toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Renal insufficiency/failure", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Cerebrovascular accident/Stroke", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "measure": "Change from baseline Torsade de pointes", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }, 
            {
                "description": "Assessed at each follow-up: 3 month, 6 month, and 12-18 month", 
                "measure": "Death", 
                "safety_issue": "Yes", 
                "time_frame": "3 month; 6 month; 12-18 month"
            }
        ], 
        "source": "La-ser Europe Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "La-ser Europe Limited", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Observational Model: Cohort", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}